TY - JOUR
TI - Impact on cytoprotective efficacy of intermediate interval between
amifostine administration and radiotherapy: A retrospective analysis
AU - Kouloulias, VE
AU - Kouvaris, JR
AU - Kokakis, JD
AU - Kostakopoulos, A and
AU - Mallas, E
AU - Metafa, A
AU - Vlahos, LJ
JO - International Journal of Radiation, Oncology, Biology, Physics
PY - 2004
VL - 59
TODO - 4
SP - 1148-1156
PB - EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
SN - 0360-3016
TODO - 10.1016/j.ijrobp.2003.12.013
TODO - interval; amifostine; radiotherapy; mucositis; dermatitis; alopecia;
retrospective analysis
TODO - Purpose: To evaluate the cytoprotective impact of the interval between
amifostine administration and radiotherapy (RT).
Methods and Materials: In a nonrandomized study, we reviewed the records
of 177 patients with tumors localized in the pelvis (prostate, bladder,
or gynecologic cancer), upper abdomen (pancreas, stomach, kidney),
thorax (lung and breast cancer), head and neck (nasopharynx), soft
tissue (sarcomas), and central nervous system. The patient records were
stratified according to whether the patients had undergone RT either
25-40 min (Group 1, 96 subjects) or 10-15 min (Group 2, 81 subjects)
after i.v. amifostine administration. The mean toxicity score was the
mean value of recorded acute radiation toxicity. The mean interruption
time was the mean value of the recorded interruption time due to
radiation toxicity.
Results: A significantly reduced severity of symptoms related to oral (p
= 0.023), esophageal (p = 0.05) and rectal (p = 0.015) mucosa was noted
in Group 2. A statistically significant reduction in the mean toxicity
score (p <0.001) and mean interruption time (p = 0.001) was observed in
Group 2 vs. Group 1. In terms of the incidence of radiation-induced
dermatitis and alopecia, multivariate logistic analysis revealed only
the total dose (P 0.018) and the amifostine-RT interval (p = 0.002) as
independent factors.
Conclusion: A significantly better cytoprotective effect of amifostine
against radiation-induced mucositis, dermatitis, and alopecia was noted
if RT was administered no later than 15 min after i.v. amifostine
infusion. The results presented here need additional investigation with
randomized prospective trials. (C) 2004 Elsevier Inc.
ER -